The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CD19/CD20 bispecific chimeric antigen receptor (CAR) in naïve/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma.
 
Sarah Marie Larson
Stock and Other Ownership Interests - 1200 Pharma; Torl Biotherapeutics
Research Funding - Abbvie; Allogene Therapeutics (Inst); BiolineRx; Bristol-Myers Squibb; Celgene; Janssen Oncology; Novartis; Pfizer (Inst); Sanofi (Inst)
 
Christopher Walthers
Employment - Orca Bio
 
Brenda Ji
No Relationships to Disclose
 
Sanaz N. Ghafouri
No Relationships to Disclose
 
Jacob Naparstek
No Relationships to Disclose
 
Jacqueline Trent
No Relationships to Disclose
 
Caitlin Harris
No Relationships to Disclose
 
Mobina Khericha Gandhi
No Relationships to Disclose
 
Thomas Schweppe
No Relationships to Disclose
 
Martin S. Auerbach
No Relationships to Disclose
 
Jonathan W. Said
No Relationships to Disclose
 
Karla Nawaly
No Relationships to Disclose
 
Monica Diane Mead
No Relationships to Disclose
 
Sven De Vos
No Relationships to Disclose
 
Patricia Young
No Relationships to Disclose
 
Caspian Oliai
No Relationships to Disclose
 
Gary J. Schiller
Stock and Other Ownership Interests - Amgen; Bristol-Myers Squibb; Johnson & Johnson
Consulting or Advisory Role - Agios; Celgene; Incyte; Jazz Pharmaceuticals; Novartis; Ono Pharmaceutical
Speakers' Bureau - Amgen; Astellas Pharma; Bristol-Myers Squibb; Jazz Pharmaceuticals; Kite, a Gilead company; Sanofi; Stemline Therapeutics
Research Funding - Abbvie; Actinium Pharmaceuticals; Actuate Therapeutics; Agios; Amgen; Arog; Astellas Pharma; Bristol-Myers Squibb/Celgene; Celator; Constellation Pharmaceuticals; Daiichi Sankyo; Deciphera; Delta-Fly Pharma; ElevateBio; FORMA Therapeutics; Fujifilm; Gamida Cell; Genentech/Roche; Geron; Incyte; Jazz Pharmaceuticals; Karyopharm Therapeutics; Kite, a Gilead company; Mateon Therapeutics; Novartis; Onconova Therapeutics; Ono Pharmaceutical; Pfizer; PrECOG; REGiMMUNE; Samus Therapeutics; Sangamo Bioscience; Sanofi; Sellas Life Sciences; Stemline Therapeutics; Takeda; Tolero Pharmaceuticals; Trovagene
 
John Timmerman
Honoraria - Kite/Gilead
Consulting or Advisory Role - DAVA Oncology; Kite/Gilead
Research Funding - Bristol-Myers Squibb; ImmunGene; Kite, a Gilead company; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Antoni Ribas
Leadership - Arcus Biosciences; Lutris; PACT Pharma
Stock and Other Ownership Interests - 4c Biomed; Advaxis; Appia Bio; Arcus Biosciences; Compugen; CytomX Therapeutics; Highlight Therapeutics; ImaginAb; ImmPACT-Bio; Inspirna; Isoplexis; Kite/Gilead; Lutris; MapKure; Merus; PACT Pharma; Pluto Immunotherapeutics; RAPT Therapeutics; Synthekine; Tango Therapeutics
Honoraria - Amgen; AstraZeneca; Chugai/Roche; Genentech/Roche; Merck Sharp & Dohme; Novartis; Sanofi; Vedanta Biosciences
Consulting or Advisory Role - Amgen; Chugai Pharma; Merck; Novartis; Sanofi
Research Funding - Agilent (Inst); Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Non-viral gene editing to Arsenal Bio
 
Yvonne Y Chen
Leadership - ImmPACT-Bio
Stock and Other Ownership Interests - Catamaran Bio; ImmPACT-Bio; Notch Therapeutics; Pluto Immunotherapeutics; Prime Medicine
Consulting or Advisory Role - Gritstone Bio; Novartis